Customer Validation
- •J Autoimmun. 2016 Feb;67:90-101.
- •J Bone Miner Res. 2015 Nov;30(11):1959-68.
- •FASEB J. 2015 Sep;29(9):3737-49.
- •Environ Toxicol Pharmacol. 2014 Sep;38(2):374-8.
- •Acta Biochim Biophys Sin (Shanghai). 2017 Apr 1;49(4):302-310.
Description |
EMD638683 is a highly selective SGK1 inhibitor with IC50 of 3 μM. |
---|---|
IC50 & Target |
IC50: 3 μM (SGK1)[1] |
In Vitro |
EMD638683 is a SGK1 inhibitor. EMD638683 inhibits the NDRG1 (N-Myc downstream-regulated gene 1) phosphorylation, an effect requiring 3.35±0.32 μM EMD638683 in the cell culture medium for half maximal effect (IC50). EMD638683 has also an inhibitory effect on cAMP-dependent protein kinase (PKA), mitogen- and stress-activated protein kinase 1 (MSK1), protein kinase C-related kinase 2 (PKR2), and the SGK isoforms SGK2 and SGK3[1]. In both, control and EMD638683 (50 µM)-treated CaCo-2 cells, radiation significantly increases the percentage of CaCo-2 cells undergoing late apoptosis. EMD638683 treatment alone tends to enhance the percentage of apoptotic CaCo-2 cells. Following radiation the percentage of apoptotic EMD638683-treated CaCo-2 cells is significantly higher than the percentage of apoptotic control cells. Thus, EMD638683 treatment significantly augments the apoptosis following radiation[2]. |
In Vivo |
The colon is significantly longer and the colon weight significantly lower in EMD638683-treated mice than in placebo-treated mice, a finding pointing to an influence of EMD638683 on tumor growth following chemical carcinogenesis. In addition, the stomach weight is significantly lower in the EMD treated group. Most importantly, the number of developing tumors following carcinogenic treatment is significantly blunted by EMD638683 treatment[2]. EMD638683 (20 mg/kg, intragastrically) prevents progression of monocrotaline (MCT)-induced pulmonary vascular remodeling in rats. Hemodynamic characteristics show that EMD638683 treatment attenuates right ventricular systolic pressure (RVSP) (15.8±2.5 vs. 28.2±3.1 mmHg; P<0.05; n="6)" and="" right="" ventricular="" hypertrophy="" index="" (rvhi)="" (0.27±0.02="" vs.="">0.05;><0.05; n="6)" compare="" to="" vehicle-dosed="">0.05;>[3]. |
References |
|
Preparing Stock Solutions |
Please refer to the solubility information to select the appropriate solvent.
|
||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cell Assay
[2] |
EMD638683 is dissolved in DMSO and stored, and then diluted with appropriate media before use[2]. Colon carcinoma (CaCo-2) cells are grown in complete DMEM medium containing 10% fetal calf serum, 1% sodium pyruvate, 1% penicillin-streptomycin and 1% non-essential amino acids under standard culture conditions (37°C, 5% CO2). 105 cells are seeded in 6 well plates and cultured with fresh culture medium for 24 h, after which EMD638683 (50 µM) is applied for 24 hours. For comparison, the cells are treated with the solvent (0.2 μL DMSO) and one solvent control is analysed with each set of experiments. The cells are subsequently exposed to 3.18 min radiation (3 Gray). After further incubation for 72 h in the presence or absence of EMD638683 (50 µM) the cells are analyzed utilizing flow cytometry[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||
Animal Administration
[3] |
EMD638683 is synthesized by Haoyuan (Shanghai, China) and dissolved in 1 % DMSO[3]. Rat and Mice[3] |
||||||||||||||||
References |
|
Molecular Weight |
364.34 |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Formula |
C₁₈H₁₈F₂N₂O₄ |
||||||||||||
CAS No. |
1181770-72-8 |
||||||||||||
Storage |
|
||||||||||||
Shipping | Room temperature in continental US; may vary elsewhere |
||||||||||||
Solvent & Solubility |
DMSO EMD638683 is fixed in 4% formaldehyde[4]. * "<1 mg/ml"="" means="" slightly="" soluble="" or="" insoluble.="" "≥"="" means="" soluble,="" but="" saturation="">1> |
||||||||||||
References |
|
Purity: 99.74%
COA (93 KB) HNMR (210 KB) LCMS (146 KB)
Handling Instructions (1252 KB)-
[1]. Ackermann TF, et al. EMD638683, a novel SGK inhibitor with antihypertensive potency. Cell Physiol Biochem. 2011;28(1):137-46.
[2]. Towhid ST, et al. Inhibition of colonic tumor growth by the selective SGK inhibitor EMD638683. Cell Physiol Biochem. 2013;32(4):838-48.
[3]. Xi X, et al. Serum-glucocorticoid regulated kinase 1 regulates macrophage recruitment and activation contributing to monocrotaline-induced pulmonary arterial hypertension. Cardiovasc Toxicol. 2014 Dec;14(4):368-78.
[4]. Zhou H, et al. Inhibition of serum- and glucocorticoid-inducible kinase 1 enhances TLR-mediated inflammation and promotes endotoxin-driven organ failure. FASEB J. 2015 Sep;29(9):3737-49.